| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/21/2001 | WO2001044325A1 Method for the emulsion polymerisation of olefins |
| 06/21/2001 | WO2001044291A2 Polynucleotid encoding the rg1 polypeptide |
| 06/21/2001 | WO2001044257A1 Proton pump inhibitors |
| 06/21/2001 | WO2001044199A1 Compounds and compositions for delivering active agents |
| 06/21/2001 | WO2001044198A1 Amphiphilic quinolylpolyamines as transfer agents for biologically active macromolecules |
| 06/21/2001 | WO2001044190A1 Anthracene derivatives as anti-cancer agents |
| 06/21/2001 | WO2001044124A1 Production of pyrogen controlled water |
| 06/21/2001 | WO2001043935A2 Injection molding method for neutral and acidic-group containing (meth)acrylate copolymers |
| 06/21/2001 | WO2001043779A2 Anti-hiv-1 conjugates for treatment of hiv disease |
| 06/21/2001 | WO2001043778A1 Use of cationic lipids for intracellular protein delivery |
| 06/21/2001 | WO2001043777A1 Complexation of rna, especially ribozymes, with polyethylenimines for the stabilization and cellular introduction thereof |
| 06/21/2001 | WO2001043776A1 Pharmaceutical formulation for intravenous or intramuscular octreotide administration |
| 06/21/2001 | WO2001043775A2 Hydroxide-releasing agents as skin permeation enhancers |
| 06/21/2001 | WO2001043762A2 Polypeptide compositions with improved stability |
| 06/21/2001 | WO2001043751A1 Novel helicobacter pylori-binding substances and use thereof |
| 06/21/2001 | WO2001043749A2 Pharmaceutical implant containing immediate-release and sustained-release components and method of administration |
| 06/21/2001 | WO2001043748A2 Implant composition containing melengestrol acetate and trenbolone acetate |
| 06/21/2001 | WO2001043747A1 Matrix tablet for prolonged release of trimetazidine after oral administration |
| 06/21/2001 | WO2001043734A2 Transdermal administration of phenylpropanolamine |
| 06/21/2001 | WO2001043729A1 Adhesive preparations |
| 06/21/2001 | WO2001043726A1 System and method for extended delivery of a therapeutic agent with its receptor loading dose |
| 06/21/2001 | WO2001043724A1 Microcapsules for sustained release of drugs |
| 06/21/2001 | WO2001043722A2 Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
| 06/21/2001 | WO2001043720A1 Composition in the form of a gel for receiving an active ingredient in a solution or suspension, especially for application on a mucous membrane and method of production thereof |
| 06/21/2001 | WO2001043714A1 The use of fluorescent whitening agents |
| 06/21/2001 | WO2001043710A1 Monofluoro phosphorylated macromolecules |
| 06/21/2001 | WO2001043702A1 Stabilizers for l-ascorbic acid-2-sodium phosphate |
| 06/21/2001 | WO2001043698A1 Topical ointment |
| 06/21/2001 | WO2001043570A1 Composition for improving the proliferative response during adaptation of the gastrointestinal tract and use in short bowel syndrome |
| 06/21/2001 | WO2001043545A2 Fluid insecticidal formulations for dermal treatment of parasitic insect larvae |
| 06/21/2001 | WO2001019871A3 Delivery system for antidandruff agent |
| 06/21/2001 | WO2001017527A9 Preventive and therapeutic agents for eye diseases |
| 06/21/2001 | WO2001013892A3 Large porous particles by spray-drying |
| 06/21/2001 | WO2001010411A3 Implantable active ingredient depot |
| 06/21/2001 | WO2001008505A9 Methods for suppressing appetite and enhancing exercise and recovery |
| 06/21/2001 | WO2000061191A9 Heat stable coated colloidal iron oxides |
| 06/21/2001 | WO1999056697A3 Pharmaceutical composition |
| 06/21/2001 | WO1998010795A9 Tumor homing molecules, conjugates derived therefrom, and methods of using same |
| 06/21/2001 | WO1997042975A9 Chitosan related compositions for delivery of nucleic acids into a cell |
| 06/21/2001 | US20010004642 Amino fruit acid composition and method for the treatment of skin |
| 06/21/2001 | US20010004637 Includes at least one of a water soluble antioxidant, a fat soluble antioxidant, a synergist, a sugar and a surfactant |
| 06/21/2001 | US20010004636 Into a mammalian parenchymal cell, by complexing a polynucleotide with a nonviral vector, amphipathic compounds, or polymer, inserting into a mammalian vessel, increasing the permeability of the vessel; use in gene therapy |
| 06/21/2001 | US20010004459 Composition with sustained release of active principle, capable of forming a microemulsion |
| 06/21/2001 | US20010004458 Rapidly disintegrating pellets |
| 06/21/2001 | DE19961334A1 Spritzgußverfahren für neutrale und säuregruppenhaltige (Meth)acrylat-Copolymere Injection method for neutral and acid group-containing (meth) acrylate copolymers |
| 06/21/2001 | DE19960775A1 Dermal applizierbare insektizide Flüssigformulierungen zur Bekämpfung von parasitierenden Insektenlarven Applied dermally insecticidal liquid formulations for controlling parasitic insect larvae |
| 06/21/2001 | DE19960099A1 Guerbet alcohols, used as oil bodies for production of cosmetic or pharmaceutical formulations, are obtained by condensing oxo-decanol and/or mixture of oxo-nonanol and oxo-undecanol |
| 06/21/2001 | DE19959419A1 Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung Stable pharmaceutical formulations comprising a benzimidazole and process for their preparation |
| 06/21/2001 | DE19959036A1 Verfahren zur Herstellung von Pulverprodukten A process for the preparation of powder products |
| 06/21/2001 | CA2396503A1 Stabilizing diluent for polypeptides and antigens |
| 06/21/2001 | CA2395289A1 Transdermal administration of phenylpropanolamine |
| 06/21/2001 | CA2395170A1 Anti-cancer agents (iii) |
| 06/21/2001 | CA2394574A1 Dna encoding a novel rg1 polypeptide |
| 06/21/2001 | CA2394569A1 Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
| 06/21/2001 | CA2394536A1 Tnfr/opg-like molecules and uses thereof |
| 06/21/2001 | CA2394416A1 Composition in the form of a gel for receiving an active ingredient in a solution or suspension, especially for application on a mucous membrane and method of production thereof |
| 06/21/2001 | CA2394213A1 Polypeptide compositions with improved stability |
| 06/21/2001 | CA2394211A1 Stabilizers for sodium l-ascorbate-2-phosphate |
| 06/21/2001 | CA2394077A1 System and method for extended delivery of a therapeutic agent with its receptor loading dose |
| 06/21/2001 | CA2393762A1 Hydroxide-releasing agents as skin permeation enhancers |
| 06/21/2001 | CA2392766A1 Novel helicobacter pylori-binding substances and use thereof |
| 06/21/2001 | CA2391957A1 Pharmaceutical implant containing immediate-release and sustained-release components and method of administration |
| 06/21/2001 | CA2391950A1 Implant composition containing melengestrol acetate and trenbolone acetate |
| 06/21/2001 | CA2391802A1 Fluid insecticidal formulations for treatment of parasitic insect larvae by dermal application |
| 06/21/2001 | CA2391358A1 Production of pyrogen controlled water |
| 06/21/2001 | CA2391259A1 Composition for improving the proliferative response during adaptation of the gastrointestinal tract and use in short bowel syndrome |
| 06/20/2001 | EP1108738A2 Immunostimulating carrier for vaccines |
| 06/20/2001 | EP1108429A2 An improved amino acid composition for providing an amino acid supplement or protein substitute, particularly for the treatment and/or management of certain diseases |
| 06/20/2001 | EP1108424A1 Matrix tablet for sustained release of trimetazidine after oral administration |
| 06/20/2001 | EP1108365A2 Encapsulated long chain alcohols |
| 06/20/2001 | EP1108364A2 Long chain alcohols admixed in sterol compounds |
| 06/20/2001 | EP1108048A1 Cationic complexes of polymer-modified adenovirus |
| 06/20/2001 | EP1108023A1 Page-4, an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor |
| 06/20/2001 | EP1108015A1 Streptavidin mutants having secondary functional domains |
| 06/20/2001 | EP1107991A1 AN ANTI-CYANOVIRIN ANTIBODY WITH AN INTERNAL IMAGE OF gp120, A METHOD OF USE THEREOF, AND A METHOD OF USING A CYANOVIRIN TO INDUCE AN IMMUNE RESPONSE TO gp120 |
| 06/20/2001 | EP1107990A1 High-affinity antibodies |
| 06/20/2001 | EP1107807A1 Method of enhancing catheter patency using a citrate salt catheter lock solution |
| 06/20/2001 | EP1107795A2 Methods and compositions for the prevention or treatment of cancer |
| 06/20/2001 | EP1107794A2 Recombinant botulinium toxin for the treatment of mucus hypersecretion |
| 06/20/2001 | EP1107793A1 Dextran-leptin conjugates, pharmaceutical compositions and related methods |
| 06/20/2001 | EP1107791A2 Hydrogel compositions for the controlled release administration of growth factors |
| 06/20/2001 | EP1107790A1 Targeting of molecules to large vessel endothelium using epcr |
| 06/20/2001 | EP1107783A1 Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor |
| 06/20/2001 | EP1107782A1 Oral vaccine compositions |
| 06/20/2001 | EP1107778A1 Treatment of disease states |
| 06/20/2001 | EP1107777A1 Stabilized pharmaceutical composition in lyophilized form |
| 06/20/2001 | EP1107775A1 Composition containing pyrrolizidine-alkaloid-free petasites |
| 06/20/2001 | EP1107772A2 Probiotic, lactic acid-producing bacteria and uses thereof |
| 06/20/2001 | EP1107762A1 Use of misoprostol or/and misoprostol acid for preparing drug in order to cure sexual dysfunction in women |
| 06/20/2001 | EP1107753A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht2 receptors |
| 06/20/2001 | EP1107750A2 Pharmaceutical composition with antitumor activity on the basis of carboplatin |
| 06/20/2001 | EP1107743A1 Stable spray-dried protein formulations |
| 06/20/2001 | EP1107741A1 Orally administered controlled drug delivery system providing temporal and spatial control |
| 06/20/2001 | EP1107740A1 Timed release tablet comprising naproxen and pseudoephedrine |
| 06/20/2001 | EP1107739A1 Method for producing solid dosing forms |
| 06/20/2001 | EP1107736A1 Microparticulate composition |
| 06/20/2001 | EP1107735A1 Omeprazole formulation |
| 06/20/2001 | EP1107734A1 Oral liquid mucoadhesive compositions |
| 06/20/2001 | EP1107733A1 Oral liquid mucoadhesive compositions |
| 06/20/2001 | EP1107732A1 Oral liquid mucoadhesive compositions |